TargetMol

SBC-115337

Product Code:
 
TAR-T9276
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T9276-1mg1mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9276-5mg5mg£269.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9276-1mL1 mL * 10 mM (in DMSO)£300.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9276-10mg10mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9276-25mg25mg£603.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9276-50mg50mg£830.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9276-100mg100mg£1,099.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9276-500mg500mg£2,135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
SBC-115337 is a PCSK9 inhibitor.
CAS:
423148-46-3
Formula:
C29H19N3O4
Molecular Weight:
473.48
Pathway:
Metabolism; Cell Cycle/Checkpoint;
Purity:
0.9981
SMILES:
O=C(C1=CC2=CC=CC=C2O1)NC3=CC=C(C(NC4=CC=C(C5=NC6=CC=CC=C6O5)C=C4)=O)C=C3
Target:
Serine/threonin kinase

References

Lavecchia A , Cerchia C . Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy[J]. Future medicinal chemistry, 2019, 11(5):423-441.